ADC Anetumab Ravtansine Does Not Improve PFS vs Paclitaxel in High-Grade Serous Ovarian Cancer
Anetumab ravtansine plus bevacizumab failed to improve efficacy vs paclitaxel plus bevacizumab in platinum-resistant high-grade ovarian cancer.
Related Articles
Fluorescent-Based Imaging with AI Can Improve Surgery in Breast and Ovarian Cancer
The FIBI technology, created by Farzad Fereidouni, PhD, when combined with AI eliminates the need for frozen sections and other labor-intensive oncology surgery practices.
Clinicians Agree With Some ChatGPT Responses to Patient Inquiries on Colon Cancer – Oncology Nurse Advisor
Researchers compared responses from ChatGPT on colon cancer with expert opinion from oncology clinicians.
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Revisit Every OncLive On Air Episode From January 2025
In case you missed any, read a recap of the episodes of OncLive On Air that aired in January 2025.
Evaluating the Risk of Second Primary Cancers After CAR T-Cell Therapy
The association of CAR T-cell therapies with second primary cancers warrants the development and examination of mitigation strategies for these toxic effects.
CARGO Therapeutics to Discontinue Phase 2 Study of Firi-Cel in R/R LBCL
CARGO Therapeutics announced that it will discontinue the phase 2 FIRCE-1 trial evaluating firi-cel in relapsed/refractory large B-cell lymphoma.
Asciminib Demonstrates Favorable Safety and Tolerability for Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Compared With Tyrosine Kinase Inhibitor Therapy
Compared with standard tyrosine kinase inhibitors, asciminib demonstrated improved safety and tolerability for the treatment of chronic myeloid leukemia, according to phase 3 data presented…
Rethinking Adjuvant Immune Therapy for Triple Negative Breast Cancer
Immunotherapy stands as one of the most transformative breakthroughs in modern cancer treatment. These innovative therapies target signaling pathways used by cancer cells to induce…
The ADC OQY-3258 Demonstrates Early Efficacy in Multiple Breast Cancer Subtypes
OQY-3258 (ESG401) showed preliminary efficacy in multiple breast cancer subtypes, including TNBC and HR+/HER2- breast cancer.